Leukemia Drug Provides Benefits in PD, Researchers Find

Leukemia Drug Provides Benefits in PD, Researchers Find

Publication date: Apr 13, 2019

While nilotinib is FDA approved for the treatment of adult patients with chronic myeloid leukemia and not PD, the drug is able to penetrate the blood-brain barrier and reduce inflammation as well as lower levels of a toxic protein that prevents the brain from utilizing dopamine stored in vessels in areas of the brain that may control movement.

While nilotinib is FDA-approved for the treatment of adult patients with chronic myeloid leukemia and not PD, the drug is able to penetrate the blood-brain barrier and reduce inflammation as well as lower levels of a toxic protein that prevents the brain from utilizing dopamine stored in vessels in areas of the brain that may control movement.

Nilotinib can also increase dopamine levels and in a 12-patient pilot study, it appeared to improve the motor and cognitive outcomes of patients with PD and dementia. In the analysis of 1 arm of a phase 2 clinical trial published in Pharmacology Research & Perspectives, researchers found that a single low dose of nilotinib increased levels of dopamine in the brains of study participants.

Concepts Keywords
Acid Pharmacodynamics
Blood Brain Barrier Alpha
Brain Pharmacokinetics
Cerebral Spinal Fluid Parkinson’s disease
Chronic Myeloid Leukemia 3,4-Dihydroxyphenylacetic acid
Clinical Trial Dopamine
Cognitive Pyrimidines
Dementia Alpha-synuclein
Dopamine Neurotransmitters
FDA Pyridines
Hebron Nilotinib
HVA Imidazoles
Inflammation Chemical compounds
Leukemia Organ systems
MBBS Branches of biology
Neurodegenerative Disorder Inflammation
Neurons Common neurodegenerative disorder
Nilotinib
Pagan
Parkinson
Parkinsonism
Pharmacodynamics
PhD
Placebo

Semantics

Type Source Name
disease MESH Leukemia
disease DOID Leukemia
drug DRUGBANK Nilotinib
disease DOID chronic myeloid leukemia
pathway BSID Chronic myeloid leukemia
disease MESH inflammation
drug DRUGBANK Dopamine
disease MESH Parkinson disease
disease DOID Parkinson disease
disease MESH neurodegenerative disorder
gene UNIPROT EGR3
disease MESH dementia
disease DOID dementia
gene UNIPROT AKR1A1
gene UNIPROT ARMC9
pathway BSID Release
disease MESH multiple
gene UNIPROT PDC
gene UNIPROT CSF2
gene UNIPROT LAMC2

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *